Denosumab Therapy for Giant Cell Tumor of Bone Pulmonary Metastasis
نویسندگان
چکیده
CASE A 68-year-old female was diagnosed with giant cell tumor of bone (GCTB) metastatic to her lungs. The patient was treated with IV denosumab for the course of 4.5 years for these metastases. The metastatic tumor burden decreased significantly after only 3 months of therapy. The size of the metastases has been stable for over 4 years. CONCLUSION Denosumab therapy has promise in the treatment of GCTB, including pulmonary metastasis. However, the long-term role of denosumab for pulmonary metastases is yet to be determined.
منابع مشابه
Denosumab in Patients with Giant Cell Tumor and Its Recurrence: A Systematic Review
Recent studies suggest that Denosumab reduces tumor size, therefore, makes the surgery easier with lowermorbidity. However, some studies have reported several complications for this drug. So, this systematic reviewwas performed to determine the effectiveness and safety of Denosumab in reducing bone destructions activity ofgiant cell tumor and skeletal-related events (SRE) in affected patients w...
متن کاملThe Epidemiologic Characteristics, Clinical Behavior and Outcome of the Giant Cell Tumor of Bone: a Retrospective Single-Center Study
Abstract Objects:Giant cell tumor of bone (GCTB) isa locally aggressive lesion with unpredictable behavior. Here, we aim to evaluate the epidemiological characteristics, clinical and functional outcome of GCTB in a relatively large series of patients. Methods:Patients with the diagnosis of GCTB were included in this retrospective study.Surgical options included extended curettage wh...
متن کاملA very rare case of metachronous multicentric giant cell tumor of bone with benign lung metastasis in form of a very large mass lesion
Giant cell tumour (GCT) is a benign, locally aggressive tumour of the bone that accounts for 5% of primary bone tumours and 21% of benign bone tumours. This tumour more commonly presents as a single (solitary) lesion; however, it may appear with multiple (multicentric) lesions in less than 1% of the cases. According to the literature, 1-9% of solitary GCTs metastasizes to the lung, more commonl...
متن کاملHistological Regression of Giant Cell Tumor of Bone Following RANK Ligand Inhibition
Lung metastases are a rare complication of giant cell tumors of bone. We herein describe an interesting case of histological regression and size reduction of lung metastases originating from a primary giant cell tumor of bone in response to the RANK ligand inhibitor denosumab.
متن کاملGolden bullet-denosumab: early rapid response of metastatic giant cell tumor of the bone.
Giant cell tumor of the bone (GCTB) is usually a benign, locally aggressive tumor with metastatic potential. Histogenesis of GCTB is unknown and a correlation has not been found between histologic and clinical course. For this reason, many authors consider its prognosis unpredictable. Lung metastasis after GCTB treatment is well known and generally has unfavorable outcome, despite varied chemot...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
دوره 2017 شماره
صفحات -
تاریخ انتشار 2017